Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Palomera
Bendamustine as Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients With Aggressive Lymphomas: Final Analysis of a Phase 2 Study From Geltamo
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Autologous Stem Cell Transplantation as Part of First-Line Therapy in Patients With Peripheral T-Cell Lymphoma: A Multicenter Geltamo/Fil Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Mitoxantrone-Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma
Turkish Journal of Medical Sciences
Medicine
Retrospective Analysis Leam Conditioning for Autologous Stem Cell Transplantation
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (With Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Thiotepa/Cyclophosphamide/Tbi as a Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome
Bone Marrow Transplantation
Transplantation
Hematology
High-Dose Therapy With Autologous Stem Cell Transplantation in Patients With Peripheral T Cell Lymphomas
Bone Marrow Transplantation
Transplantation
Hematology
A Reduced-Intensity Conditioning Regimen for Patients With Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Impact of Conditioning Regimen on Outcomes for Patients With Lymphoma Undergoing High-Dose Therapy With Autologous Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Results of a Prospective Phase II Trial With Ofatumumab as Part of Reduced Intensity Conditioning Regimen in High-Risk Non-Hodgkin B Lymphoma Patients: A GELTAMO Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
